Mineralys Therapeutics
The Vice President, Global Marketing at Mineralys Therapeutics will lead the development and execution of the company's ex-U.S. commercial strategy, shaping global market entry, partnership, and revenue plans. This senior leader will work cross‑functionally with clinical, regulatory, market access, and business development teams to align global initiatives with U.S. objectives and drive long‑term growth.
Headquarters
Radnor, Pennsylvania, United States
Company Size
11-50 employees
Founded
2020
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on improving outcomes for people with hypertension, chronic kidney disease (CKD), and cardio-renal-metabolic diseases driven by dysregulated aldosterone. The company's lead investigational candidate, Lorundrostat, is designed to target the underlying role of aldosterone in these conditions. Mineralys is advancing its pipeline through clinical development with the goal of delivering better outcomes for patients inadequately served by current therapies.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Mineralys Therapeutics.
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight
3 days ago